Full Press Release Details
Kewaunee Scientific Declares Quarterly Dividend
and Reports Results for Third Quarter
| Exchange: | NASDAQ (KEQU) | Contact: | Thomas D. Hull III | |||
| (704) 871-3290 |
STATESVILLE, N.C. February 26, 2019 PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today reported
results for its third quarter of fiscal year 2019, ended January 31, 2019.
Sales for the quarter were $32,372,000, a 15.2% decrease from sales of
$38,190,000 in the prior year third quarter. Domestic sales for the quarter were $25,217,000, down 15.2% from sales of $29,734,000 in the third quarter of last year. International sales for the quarter were $7,155,000, down 15.4% from sales of
$8,456,000 in the third quarter last year.
Domestic sales decreased year-over-year as the activity in the marketplace slowed dramatically throughout the
quarter. The slowdown, felt across the Company s direct, dealer, and distribution channels, reduced production below the rate necessary to generate favorable financial results. International sales decreased similarly, with strength in the
Indian market being offset by softness in the Middle East and Asian markets. Also negatively impacting Kewaunee s International segment performance was a year-over-year decline in the exchange rate of the Indian rupee versus the US dollar.
Pre-tax earnings for the quarter were $35,000 compared to $2,484,000 for the prior year period. Pre-tax earnings were impacted by the year-over-year decline in sales, increases in raw material costs and the previously mentioned foreign exchange impact. Net earnings decreased 103% for the quarter to a loss of
($22,000), or ($0.01) per diluted share, as compared to net earnings of $883,000, or $0.31 per diluted share, for the quarter ended January 31, 2018.
The Company s order backlog is $96 million at January 31, 2019, as compared to $101 million at October 31, 2018 and $116 million
at January 31, 2018. The Company continues to have a strong volume of outstanding quotations globally and is aggressively pursuing these projects.
The Company s balance sheet and financial condition remain strong. Unrestricted cash on hand was $10.8 million at the end of the quarter, as
compared to $9.2 million at the end of the third quarter last year. Working capital was $36.1 million, as compared to $36.2 million at the end of the third quarter last year. Short-term debt and interest rate swaps were
$5.1 million at the end of the quarter, as compared to $4.8 million at the end of the third quarter last year, and long-term debt was $526,000 as compared to $1.6 million at the end of the third quarter last year. The debt-to-equity ratio at January 31, 2019 was .14-to-1, as compared to .16-to-1 at January 31, 2018.
The third quarter is traditionally the Company s softest quarter as it falls around customers calendar year-end as well as the holidays. This quarter was especially challenging as expected orders were delayed, resulting in our facilities being under-utilized. The quarter was also impacted by substantially higher raw
material costs in steel and resin as compared to the prior year third quarter.
There still remains a significant amount of activity for our products and
services both domestically and abroad; however, economic and geopolitical uncertainty have caused many customers to postpone awards as well as the start of new projects, said David M. Rausch, Kewaunee s President and Chief Executive
Officer. Looking forward, we anticipate these trends will continue through the remainder of the fiscal year and are making the necessary adjustments to return to profitability in the fourth quarter.
In other news, the Company s Board of Directors declared a quarterly cash dividend of nineteen cents per outstanding share, payable on March 25,
2019 to stockholders of record at the close of business on March 11, 2019.
About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and
technical furniture products. The Company s products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safely cabinets, and epoxy resin worksurfaces and
The Company s corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States,
India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The
Company s China headquarters and sales office are located in Shanghai, China. Kewaunee Scientific s website is located at http://www.kewaunee.com.
This press release contains statements that the Company believes to be forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company s future financial condition, results of operations, business operations and
business prospects, are forward-looking statements. Words such as anticipate, estimate, expect, project, intend, plan, predict, believe and similar
words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and
economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company s filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Kewaunee Scientific Corporation
Condensed Consolidated Statements of Operations (Unaudited)
($ and shares in thousands, except per share amounts)
| Three months ended January 31, | Nine months ended January 31, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Net sales | $ | 32,372 | $ | 38,190 | $ | 111,802 | $ | 113,542 | ||||||||
| Cost of products sold | 27,142 | 29,836 | 91,325 | 90,456 | ||||||||||||
| Gross profit | 5,230 | 8,354 | 20,477 | 23,086 | ||||||||||||
| Operating expenses | 5,305 | 5,971 | 17,031 | 16,360 | ||||||||||||
| Operating earnings (loss) | (75 | ) | 2,383 | 3,446 | 6,726 | |||||||||||
| Other income | 186 | 179 | 500 | 524 | ||||||||||||
| Interest expense, net | (76 | ) | (78 | ) | (258 | ) | (226 | ) | ||||||||
| Earnings before income taxes | 35 | 2,484 | 3,688 | 7,024 | ||||||||||||
| Income tax expense | 20 | 1,566 | 803 | 3,149 | ||||||||||||
| Net earnings | 15 | 918 | 2,885 | 3,875 | ||||||||||||
| Less: net earnings attributable to the noncontrolling interest | 37 | 35 | 86 | 120 | ||||||||||||
| Net earnings (loss) attributable to Kewaunee Scientific Corporation | $ | (22 | ) | $ | 883 | $ | 2,799 | $ | 3,755 | |||||||
| Net earnings (loss) per share attributable to | ||||||||||||||||
| Kewaunee Scientific Corporation stockholders | ||||||||||||||||
| Basic | ($ | 0.01 | ) | $ | 0.32 | $ | 1.02 | $ | 1.38 | |||||||
| Diluted | ($ | 0.01 | ) | $ | 0.31 | $ | 1.00 | $ | 1.35 | |||||||
| Weighted average number of common shares outstanding | ||||||||||||||||
| Basic | 2,744 | 2,722 | 2,741 | 2,717 | ||||||||||||
| Diluted | 2,794 | 2,784 | 2,799 | 2,772 |
Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
| January 31, 2019 | April 30, 2018 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 10,771 | $ | 9,716 | ||||
| Restricted cash | 606 | 1,242 | ||||||
| Receivables, less allowances | 27,929 | 32,660 | ||||||
| Inventories | 16,672 | 17,662 | ||||||
| Prepaid expenses and other current assets | 3,778 | 2,224 | ||||||
| Total Current Assets | 59,756 | 63,504 | ||||||
| Net property, plant and equipment | 15,202 | 14,661 | ||||||
| Other assets | 4,604 | 6,193 | ||||||
| Total Assets | $ | 79,562 | $ | 84,358 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Short-term borrowings and interest rate swaps | $ | 5,118 | $ | 3,885 | ||||
| Current portion of long-term debt and lease obligations | 1,184 | 1,167 | ||||||
| Accounts payable | 11,106 | 14,754 | ||||||
| Other current liabilities | 6,298 | 7,756 | ||||||
| Total Current Liabilities | 23,706 | 27,562 | ||||||
| Other non-current liabilities | 6,345 | 9,275 | ||||||
| Total Liabilities | 30,051 | 36,837 | ||||||
| Kewaunee Scientific Corporation equity | 48,990 | 47,059 | ||||||
| Noncontrolling interest | 521 | 462 | ||||||
| Total Stockholders Equity | 49,511 | 47,521 | ||||||
| Total Liabilities and Stockholders Equity | $ | 79,562 | $ | 84,358 |